Ko, Andrew H.
https://orcid.org/0000-0001-8196-7907
Mayo Clinic
University of California, San Francisco
Citations 12
Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Ko, Andrew H. , Chiorean, E. Gabriela , Kwak, Eunice L., Lenz, Heinz‐Josef , Nadler, Paul I., Wood, Debra L., Fujimori, Masamoto, Inada, Tetsuhi, Kouji, Hiroyuki , Fujimori, Masamoto, McWilliams, Robert R.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15721-e15721
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
Fuchs, Charles S. , Doi, Toshihiko , Jang, Raymond Woo-Jun, Muro, Kei , Machado, Manuela , Sun, Weijing , Jalal, Shadia I. , Metges, Jean-Phillipe, Garrido, Marcelo , Golan, Talia , Mandalà, Mario , Catenacci, Daniel V.T. , Ohtsu, Atsushi , Shitara, Kohei , Geva, Ravit , Bleeker, Jonathan , Ko, Andrew H. , Philip, Philip, Enzinger, Peter C. , Levitan, Diane, Wang, Jiangdian, Rosales, Minori Koshiji, Dalal, Rita P., Yoon, Harry H. , Satoh, Taroh , Shah, Manish A , Metges, Jean‐Philippe , Wainberg, Zev A. , Ku, Geoffrey , Bang, Yung‐Jue
JAMA Oncology | March 15, 2018 | Volume: 4 | Issue: 5 | Pages: e180013